tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Teladoc (TDOC) and NeoGenomics (NEO)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDTResearch Report), Teladoc (TDOCResearch Report) and NeoGenomics (NEOResearch Report).

Medtronic (MDT)

BTIG analyst Ryan Zimmerman maintained a Hold rating on Medtronic yesterday. The company’s shares closed last Tuesday at $85.85.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 12.9% and a 51.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Tactile Systems Technology, and Treace Medical Concepts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Medtronic with a $92.64 average price target, which is a 6.5% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Teladoc (TDOC)

In a report released yesterday, David Larsen from BTIG maintained a Hold rating on Teladoc. The company’s shares closed last Tuesday at $20.49.

According to TipRanks.com, Larsen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.0% and a 35.2% success rate. Larsen covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Simulations Plus, and Health Catalyst.

The word on The Street in general, suggests a Hold analyst consensus rating for Teladoc with a $22.89 average price target, a 10.6% upside from current levels. In a report issued on February 6, Bank of America Securities also maintained a Hold rating on the stock with a $24.00 price target.

NeoGenomics (NEO)

BTIG analyst Mark Massaro reiterated a Buy rating on NeoGenomics yesterday and set a price target of $23.00. The company’s shares closed last Tuesday at $14.70.

According to TipRanks.com, Massaro has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -15.7% and a 30.8% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, BioNano Genomics, and Guardant Health.

NeoGenomics has an analyst consensus of Strong Buy, with a price target consensus of $21.50, a 53.4% upside from current levels. In a report issued on February 14, Leerink Partners also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MDT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles